On Tuesday, researchers announced that a three-drug cocktail may help women with HER2-positive breast cancer better than any other drug used on its own. About one quarter of women with breast cancer make up this HER2 category.

Tests on mice revealed using the three drugs along with breast cancer drug tamoxifen helped wipe out tumors altogether. And the tumors did not come back. This is the first time mice were cured of a very aggressive human breast tumor. Incidentally, when a single drug was used, tumors returned within several weeks.

The three wonder drugs used in this study -- all are monoclonal antibodies that precisely target certain aspects of tumors -- are the experimental drug pertuzumab; trastuzumab, also known as Herceptin; and gefitinib, or Iressa.

Published in the Journal of the National Cancer Institute, this study supports the notion that HER2-positive tumors eventually become resistant to one drug and attacking them on several fronts seems to work better.

There's a new vaccine out there that stimulates the immune system to find and destroy breast cancer cells. In early experiments, the vaccine held off or stopped the growth of tumors in all of the mice studied. Some mice were even cured.

Think about this:

Research presented at the annual meeting of the American Association for Cancer Research reveals this vaccine is different from most under development that help kick-start the immune systems of sick patients. In this case, the vaccine tells the immune system to recognize breast cancer cells and to attack and kill them on the spot.

One researcher says breast cancer cells usually fly under the radar of the immune system. To combat this problem, the injectable vaccine uses a bacteria-type substance that is altered to contain the gene HER2/neu and also antibodies that rev up the immune system. This makes the body react and wipe out cells containing HER2/neu.

If continued studies prove promising, the vaccine would work for the 15 to 25 percent of women whose breast cancers overexpress HER2/neu.

A therapy that may block further metastasis from breast cancer is being studied in the lab. The monoclonal antibody, known as JAA-F11, was shown to create a survival advantage in mice with breast cancer and substantially reduce the development of lung metastasis.

The monoclonal antibody inhibited the adhesion to the breast tumor cells to endothelial cells, which would block a key step in metastasis. The study showed that 53 percent of treated mice had no visible lung metastasis.

Dr. Rittenhouse-Olson, of the University at Buffalo, New York, concluded "If JAA-F11 were linked to a radioactive compound, it may be successful in conjunction with current chemotherapy in decreasing or eliminating the tumor".

Understanding more about antibodies, antigens and monoclonal antibodies:

Disease causing bacteria and viruses, known as antigens, are recognized by the body's own immune system as invaders. Our natural defenses against these infectious agents are antibodies, proteins that seek out the antigens and help destroy them.

Each antibody binds to and attacks one specific antigen. Antibodies also can continue resistance, for example, we can acquire chickenpox when we are children and most times never experience the disease again.

This characteristic of antibodies achieving resistance makes it possible to develop vaccines. A vaccine when entered into the body, stimulates the production of antibodies against the specific antigen.

Monoclonal antibody technology allow us to produce large amounts of pure antibodies obtaining cells that produce antibodies naturally, in effect having a factory to produce antibodies that worked around the clock. The antibodies are called monoclonal because they come from only one type of cell.

Stomach cancer is hard to detect. It has no symptoms in its early stages, and there is no effective screening to detect its presence. So early detection and early treatment for this disease -- that attacks 800,000 people worldwide -- are hard to come by. In Taiwan, stomach cancer is the fifth most common cancer and the focus of study for researchers working to devise a method for detecting stomach cancer in its infancy.

A team of researchers at National Taiwan University Hospital have discovered a toxic factor -- GroES -- that causes stomach cancer. And they have discovered that a simple blood test will show either a positive or negative result for this substance, leading to immediate endoscopic exams for patients who may be at risk for stomach cancer. The test to identify GroES has already achieved a 65 percent accuracy rate.

Apparently, if the human body is infected with GroES, it produces antibodies to the factor and can cause chronic inflammation of the stomach, causing cells to rupture and proliferate. Long-term inflammation can cause stomach cancer. Researchers say about 45 percent of adults in Taiwan are infected with GroES -- and one percent will go on to develop stomach cancer.

Right now, patent applications are underway in the United States, Japan, and Taiwan. Once a kit is developed, a single drop of blood will be all it takes to determine the risk for stomach cancer.

Hormone refractory prostate cancer is when the prostate cancer cells continue to grow after an initial period of success with hormonal therapy. Most prostate cancers are hormone dependent and require male sex hormones to grow, usually over time the prostate cancer cells develop the ability to grow in the absence of the male hormones.

In this randomized Phase III trial, men with hormone refractory prostate cancer that has metastasized will receive standard chemotherapy with the drugs docetaxel and prednisone. Half of the participants will be randomly assigned to additionally receive treatment with a monoclonal antibody called bevacizumab (Avastin).

Avastin works by stopping some cancers from developing new blood vessels. This reduces the cancer's supply of oxygen and nutrients, which causes the tumor to shrink, or at least to stop growing. Drugs that interfere with blood vessel growth in this way are called angiogenesis inhibitors or anti-angiogenics.

This Phase III trial will answer the question of whether adding bevacizaumab to docetaxal and prednisone actually does improve survival over the current standard of care.

You can join this trial that researchers will enroll 1,020 men with metatastic prostate cancer that is progressing despite hormone therapy by going to see the list of eligibility criteria.

Cancer vaccines continue to be seen as significant progress in cancer prevention. As an example, cervical cancer vaccines have proven to be so successful in all clinical trials, the vaccines will become available for women this summer. If you watch television, you might have seen the new ad campaign directed as raising awareness for women regarding the virus associated with cervical cancer.

Now, the University of Arkansas for Medical Sciences Arkansas Cancer Research Center has been awarded a $2.9 million federal grant to study a new type of carbohydrate-targeting vaccine to prevent the recurrence of breast cancer. One important carbohydrate present on breast cancer cells is the Lewis Y, LeY, antigen. The vaccine would provide antibodies to LeY that have been shown effective in killing breast cancer cells. According to the researchers, previous clinical studies have shown that the survival rate for cancer patients with other types of cancer increases with carbohydrate-targeting antibodies. Before now, this has not been tested in regard to breast cancer. Won't it be nice, if one day, preventing some cancers is a matter of getting properly vaccinated.